Skip to content
Companies

CoRegen

Cancer therapy that reprograms regulatory T cells

Raised to date

$96.9M

of $96.9M offered across 3 Form D filings

Investors
7
Last filed
Feb 26, 2026

About

CoRegen, Inc. is a pioneering biopharmaceutical company dedicated to the development of innovative treatments aimed at aggressive cancers and chronic diseases. Utilizing its proprietary master gene regulator platform, CoRegen works on harnessing the body’s immune system to combat cancer effectively.

CoRegen stands out by deploying a unique strategy of targeting multiple immune checkpoint genes simultaneously, which promotes robust anti-tumor effects that may surpass traditional therapies.

Funding

$62.6M round, first sold Apr 2025$62.6M sold20252026
Now
  • EquityFiled Feb 26, 2026Form D
    $13.5M/ $13.5M
  • EquityFiled May 22, 2025Form D
    $62.6M/ $62.6M
  • EquityFiled Feb 28, 2025Form D
    $20.8M/ $20.8M

Product

Novel Cancer Therapy

Cancer Therapy

CoRegen's main product is a cutting-edge cancer therapy designed to modify regulatory T cells (Tregs) with the aim of eliminating tumors and preventing their recurrence. The therapy focuses on effectively enhancing the immune response against cancer cells.

  • Simultaneous targeting of multiple immune checkpoint genes
  • Ability to completely eradicate established tumors in preclinical studies
  • Prevention of tumor recurrence without toxicity or off-target effects

Built for

Patients with aggressive or difficult-to-treat cancers

People on file